Dispelling the myth: Incorporating β-blockers into practice guidelines

Milton Packer

Research output: Contribution to journalArticlepeer-review


Compelling data from multiple clinical trials have revealed a significant reduction in mortality risk among heart failure patients who are treated with β-blockers. The magnitude of the benefit is 30% to 35%, and the data have indicated a reduction of at least 35% to 40% in the risk of death or hospitalization for worsening heart failure. The message contained in those data has yet to be heard by many physicians in clinical practice. Underuse of β-blockers as heart failure therapy remains a major obstacle to improved treatment. The rationale for use of β-blockers in the treatment of heart failure is at least as sound as the justification for use of angiotensin-converting enzyme inhibitors. The weight of the clinical evidence has created a mandate for prescribing β-blockers for the vast majority of stable class II or III heart failure patients.

Original languageEnglish (US)
Pages (from-to)S313-S317
JournalAmerican Journal of Managed Care
Issue number6 SUPPL.
StatePublished - Apr 1 2000

ASJC Scopus subject areas

  • Health Policy


Dive into the research topics of 'Dispelling the myth: Incorporating β-blockers into practice guidelines'. Together they form a unique fingerprint.

Cite this